摘要
目的:观察云克联合甲氨蝶呤、来氟米特治疗类风湿关节炎的远期疗效。方法:将57例类风湿关节炎患者分为2组,治疗组30例采用静脉滴注云克,口服甲氨蝶呤+来氟米特治疗;对照组27例采用单纯口服甲氨蝶呤+来氟米特治疗。观察治疗前及治疗后4、12周时的关节症状、实验室指标变化,并评价其疗效和不良反应。结果:治疗4周后,治疗组达到美国风湿病学会(ACR)20为27例(90.00%),ACR50为7例(23.33%);对照组达到ACR20为18例(67.00%),ACR50为0,2组比较差异均有统计学意义(P<0.05);治疗后12周治疗组达到ACR50为21例(70.00%),ACR70为9例(30.00%);对照组达到ACR50为9例(33.33%),ACR70为2例(7.41%),2组比较差异有统计学意义(P<0.01)。2组不良反应比较差异无统计学意义(P>0.05)。结论:云克联合甲氨蝶呤、来氟米特治疗类风湿关节炎远期效果、安全性好。
OBJECTIVE：To observe the long-term efficacy of 99Tc-MDP combined with methotrexate（MTX）and leflunomide（LEF）on rheumatoid arthritis.METHODS：57 patients with rheumatoid arthritis were randomly divided into 2 groups.30 patients in the control group were given 99Tc-MDP combined with MTX and LEF,and 27 patients in the control group were given oral drugs only.The joint symptoms,change of laboratory indexes were measured in 2 groups before treatment and 4 weeks and 12 weeks after treatment.The curative effect was also evaluated.RESULTS：4 weeks after treatment,in treatment group,27 cases came to ACR20,accounting for 90.00%,and 7 cases came to ACR50,accounting for 23.33%;in control group 18 cases came to ACR20,accounting for 67.00%,and 0 case came to ACR50.There were difference between the 2 groups（P0.05）.12 weeks after treatment,in treatment group,21 cases came to ACR50,accounting for 70.00%,and 9 cases came to ACR70,accounting for 30.00%;in control group,9 cases came to ACR50,accounting for 33.33%,and 2 cases came to ACR70,accounting for 7.41%.There were statistically difference between the 2 groups（P0.01）.CONCLUSION：Combination therapy of 99Tc-MDP has good long-term efficacy in the treatment of rheumatoid arthritis.
出处
《中国药房》
CAS
CSCD
2012年第16期1485-1487,共3页
China Pharmacy
关键词
云克
甲氨蝶呤
来氟米特
类风湿关节炎
远期疗效
99Tc-MDP
Methotrexate
Leflunomide
Rheumatoid arthritis
Long-term efficacy
